Key Points
- CEO Nikhil Lalwani sold 5,400 ANI Pharmaceuticals shares for approximately $401,220 under a pre-arranged Rule 10b5-1 trading plan, reducing his direct stake by 1.54% to 344,489 shares.
- ANI Pharmaceuticals reported strong quarterly results, with EPS of $2.21 beating estimates by $0.17 and revenue of $266.04 million rising 25.8% year over year. The company issued fiscal 2026 EPS guidance of $9.19–$9.69.
- Analyst sentiment remains a “Moderate Buy”, with four Buy and four Hold ratings and an average price target of $105.83 versus a recent share price near $74.56; institutional investors own 76.05% of the stock.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) CEO Nikhil Lalwani sold 5,400 shares of the stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $74.30, for a total transaction of $401,220.00. Following the transaction, the chief executive officer directly owned 344,489 shares in the company, valued at $25,595,532.70. This trade represents a 1.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
ANI Pharmaceuticals Stock Performance
Shares of ANI Pharmaceuticals stock opened at $74.56 on Thursday. ANI Pharmaceuticals, Inc. has a one year low of $70.15 and a one year high of $99.50. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of 16.07 and a beta of 0.44. The business has a 50-day simple moving average of $79.93 and a 200 day simple moving average of $78.75. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41.
ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The business had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. During the same quarter in the prior year, the company earned $1.80 earnings per share. The company's quarterly revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, research analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on ANIP. Guggenheim cut their target price on ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating on the stock in a report on Monday, August 10th. Weiss Ratings downgraded shares of ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a report on Tuesday, August 11th. Zacks Research downgraded shares of ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 14th. Wall Street Zen downgraded ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 8th. Finally, Canaccord Genuity Group lowered their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a research report on Monday, August 10th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $105.83.
Read Our Latest Report on ANIP
Institutional Trading of ANI Pharmaceuticals
A number of hedge funds have recently bought and sold shares of the business. KBC Group NV purchased a new position in ANI Pharmaceuticals in the first quarter worth $28,000. Advisors Asset Management Inc. purchased a new stake in shares of ANI Pharmaceuticals during the 1st quarter valued at $28,000. Hantz Financial Services Inc. raised its stake in shares of ANI Pharmaceuticals by 70.3% during the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company's stock worth $48,000 after purchasing an additional 249 shares during the period. Kemnay Advisory Services Inc. purchased a new position in shares of ANI Pharmaceuticals in the 4th quarter worth about $48,000. Finally, State of Wyoming purchased a new position in shares of ANI Pharmaceuticals in the 2nd quarter worth about $50,000. 76.05% of the stock is currently owned by institutional investors.
About ANI Pharmaceuticals
(
Get Free Report)
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
